LEADER 02462nam 2200673 a 450 001 9910451406803321 005 20200520144314.0 010 $a1-4129-2133-3 010 $a1-281-24520-8 010 $a9786611245207 010 $a1-84787-864-4 035 $a(CKB)1000000000411484 035 $a(EBL)334349 035 $a(OCoLC)290537149 035 $a(SSID)ssj0000131885 035 $a(PQKBManifestationID)11129707 035 $a(PQKBTitleCode)TC0000131885 035 $a(PQKBWorkID)10028087 035 $a(PQKB)10959578 035 $a(MiAaPQ)EBC334349 035 $a(StDuBDS)EDZ0000072196 035 $a(PPN)238400573 035 $a(Au-PeEL)EBL334349 035 $a(CaPaEBR)ebr10218296 035 $a(CaONFJC)MIL124520 035 $a(EXLCZ)991000000000411484 100 $a20120412d2007 fy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCreating citizen-consumers$b[electronic resource] $echanging publics & changing public services /$fJohn Clarke ... [et al.] 210 $aLondon $cSAGE$d2007 215 $a1 online resource (192 p.) 300 $aTitle appears 3 times on t.p. 311 $a1-4462-1355-2 311 $a1-4129-2134-1 320 $aIncludes bibliographical references (p. [164]-175) and index. 327 $aCover; Contents; Preface; Introduction; Chapter 1; Chapter 2; Chapter 3; Chapter 4; Chapter 5; Chapter 6; Chapter 7; Chapter 8; Appendix; References; Index 330 8 $a'Creating Citizen-Consumers' explores a range of theoretical political and practice issues that arise in the shift towards consumerism. It makes a distinctive contribution to debates about the future of public services as well as contextualising current thinking. 606 $aHuman services$zGreat Britain 606 $aHuman services$zGreat Britain$xDecision making$xCitizen participation 606 $aCitizenship 606 $aConsumption (Economics) 607 $aGreat Britain$xSocial policy 608 $aElectronic books. 615 0$aHuman services 615 0$aHuman services$xDecision making$xCitizen participation. 615 0$aCitizenship. 615 0$aConsumption (Economics) 676 $a361.941 701 $aClarke$b John$f1950-$0864799 801 0$bStDuBDS 801 1$bStDuBDS 906 $aBOOK 912 $a9910451406803321 996 $aCreating citizen-consumers$92477618 997 $aUNINA LEADER 01443nam 2200457 450 001 9910465975703321 005 20200520144314.0 010 $a0-87020-804-7 035 $a(CKB)3710000000886444 035 $a(MiAaPQ)EBC4699613 035 $a(Au-PeEL)EBL4699613 035 $a(CaPaEBR)ebr11272397 035 $a(OCoLC)960276806 035 $a(EXLCZ)993710000000886444 100 $a20161011h20162016 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aAlexander Hamilton $efrom obscurity to greatness /$fcompiled and edited by John P. Kaminski 210 1$a[Madison, Wisconsin] :$cWisconsin Historical Society Press,$d2016. 210 4$dİ2016 215 $a1 online resource (245 pages) 225 0 $aWord portraits of America's Founders 311 $a0-87020-803-9 320 $aIncludes bibliographical references and index. 606 $aStatesmen$zUnited States$vBiography$vSources 607 $aUnited States$xPolitics and government$y1775-1783$vSources 607 $aUnited States$xPolitics and government$y1783-1809$vSources 608 $aElectronic books. 615 0$aStatesmen 676 $a973.4092 702 $aKaminski$b John P. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910465975703321 996 $aAlexander Hamilton$92117202 997 $aUNINA LEADER 02172oam 2200325z- 450 001 9910830042603321 005 20210108010103.0 010 $a1-119-07030-9 010 $a1-119-07029-5 010 $a1-119-07015-5 035 $a(CKB)4330000000008301 035 $a(MiAaPQ)EBC5452560 035 $a(EXLCZ)994330000000008301 100 $a20180812cuuuuuuuu -u- - 101 0 $aeng 200 00$aOligonucleotide-based drugs and therapeutics $epreclinical and clinical considerations for development /$fedited by Nicolay Ferrari, Rosanne Seguin 210 $cJohn Wiley & Sons, Inc 311 $a1-118-53733-5 327 $aMechanisms of oligonucleotide actions -- The medicinal chemistry of antisense oligonucleotides -- Cellular pharmacology of antisense oligonucleotides -- Pharmacokinetics and pharmacodynamics of antisense oligonucleotides -- Tissue distribution, metabolism and clearance -- Hybridization-independent effects : principles and specific considerations for oligonucleotide drugs -- Hybridization-dependent effects : the prediction, evaluation and consequences of unintended target hybridization -- Class-related proinflammatory effects -- Exaggerated pharmacology -- Genotoxicity tests for novel oligonucleotide-based therapeutics -- Reproductive and developmental toxicity testing strategies for oligonucleotide-based therapeutics -- Specific considerations for preclinical development of inhaled oligonucleotides -- Lessons learned in oncology programs -- Inhaled antisense for treatment of respiratory disease -- Antisense oligonucleotides for treatment of neurology diseases -- Nucleic acids as adjuvants -- Splice-switching oligonucleotides -- CMC aspects for the clinical development of spiegelmers. 606 $aOligonucleotides$xTherapeutic use 606 $aAntisense nucleic acids$xTherapeutic use 615 0$aOligonucleotides$xTherapeutic use. 615 0$aAntisense nucleic acids$xTherapeutic use. 676 $a572.8/5 702 $aFerrari$b Nicolay$f1969- 702 $aSeguin$b Rosanne 906 $aBOOK 912 $a9910830042603321 996 $aOligonucleotide-based drugs and therapeutics$94049150 997 $aUNINA